{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:13:00Z","timestamp":1789423980031,"version":"build-2803163510"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Benzodiazepines are prescribed for the treatment of adolescent sleep disorders; however, benzodiazepine overdoses occur, often in combination with opioids.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate whether benzodiazepine treatment for sleep disorders, compared with alternative pharmacologic treatments (trazodone, hydroxyzine, zolpidem, zaleplon, and eszopiclone), is associated with increased risk of drug overdose for young people.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study included privately insured people 10 to 29 years of age identified from a US commercial claims database (MarketScan), from January 1, 2009, to December 31, 2018. Young people with a sleep disorder diagnosis initiating benzodiazepine (n\u2009=\u200923\u202f084) or comparator pharmacologic treatments (n\u2009=\u200966\u202f706) were included in the study. Statistical analysis was performed from November 1, 2021, to May 16, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>New use of benzodiazepine treatment or comparator pharmacologic treatments (defined as \u22651 year without a prescription for benzodiazepine or comparator medications).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Incident diagnosed drug overdoses were identified from inpatient and emergency department records within 6 months of treatment initiation. The propensity score\u2013adjusted cumulative incidence of overdose and hazard ratios (HRs) were estimated with intention-to-treat (analyzed based on initial treatment) and as-treated analyses (added censoring at treatment discontinuation). Results were stratified by prior prescription opioid fill.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 23\u202f084 young people initiating benzodiazepine treatment (14\u202f444 female participants [62.6%]; mean [SD] age, 23 [4.1] years) and 66\u202f706 initiating a comparator treatment (38\u202f446 female participants [57.6%]; mean [SD] age, 22 [4.4] years). Six months after treatment initiation, 9.7% (95% CI, 9.3%-10.1%) of benzodiazepine users and 12.3% (95% CI, 12.1%-12.6%) of the comparator group were still receiving treatment. The crude incidence of drug overdose at 6 months was 0.9% for benzodiazepine initiators and 0.8% for comparator treatment initiators. In adjusted analyses, an increased risk of drug overdose was associated with benzodiazepines vs comparator treatments (intention-to-treat analysis: HR, 1.25 [95% CI, 1.03-1.51]; as-treated analysis: HR, 1.44 [95% CI, 1.14-1.80]). This association was stronger among young people with a recent prescription opioid fill vs those without a recent prescription opioid fill (as-treated analysis: adjusted HR, 2.01 [95% CI, 1.24-3.25] vs adjusted HR, 1.31 [95% CI, 1.00-1.70]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this study suggest that benzodiazepines, compared with alternative pharmacologic treatments for common sleep disorders, were associated with an increased risk of drug overdose among young people during the following 6-month period, especially among those with a recent opioid prescription. Drug overdose is an important safety consideration when treating young people with benzodiazepines.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.43215","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T16:00:32Z","timestamp":1669132832000},"page":"e2243215","source":"Crossref","is-referenced-by-count":21,"title":["Association of Benzodiazepine Treatment for Sleep Disorders With Drug Overdose Risk Among Young People"],"prefix":"10.1001","volume":"5","author":[{"given":"Greta A.","family":"Bushnell","sequence":"first","affiliation":[{"name":"Center for Pharmacoepidemiology and Treatment Sciences, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey"},{"name":"Department of Biostatistics and Epidemiology, Rutgers University School of Public Health, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gerhard","sequence":"additional","affiliation":[{"name":"Center for Pharmacoepidemiology and Treatment Sciences, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey"},{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Keyes","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hasin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York"},{"name":"Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[{"name":"Center for Opioid Epidemiology and Policy, Department of Population Health, New York University School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York"},{"name":"Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"zoi221218r1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwac010","article-title":"Age, period, and cohort effects of internalizing symptoms among US students and the influence of self-reported frequency of attaining 7 or more hours of sleep: results from the Monitoring the Future Survey 1991-2019.","author":"Kaur","year":"2022","journal-title":"Am J Epidemiol"},{"key":"zoi221218r2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.smrv.2017.06.009","article-title":"Insomnia disorder in adolescence: diagnosis, impact, and treatment.","volume":"39","author":"de Zambotti","year":"2018","journal-title":"Sleep Med Rev"},{"issue":"7","key":"zoi221218r3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S2215-0366(20)30136-X","article-title":"Sleep disturbance and psychiatric disorders.","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"zoi221218r4","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1542\/peds.2019-2056I","article-title":"Sleep disorders in adolescents.","volume":"145","author":"Kansagra","year":"2020","journal-title":"Pediatrics"},{"issue":"1","key":"zoi221218r5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13643-019-1163-9","article-title":"Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews.","volume":"8","author":"Rios","year":"2019","journal-title":"Syst Rev"},{"issue":"6","key":"zoi221218r6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.2017.26.issue-6","article-title":"European guideline for the diagnosis and treatment of insomnia.","volume":"26","author":"Riemann","year":"2017","journal-title":"J Sleep Res"},{"issue":"2","key":"zoi221218r7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline.","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"zoi221218r8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.chc.2009.04.009","article-title":"Pharmacologic treatment of pediatric insomnia.","volume":"18","author":"Owens","year":"2009","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"6","key":"zoi221218r9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.amepre.2019.07.006","article-title":"Prescription benzodiazepine use in privately insured U.S. children and adolescents.","volume":"57","author":"Bushnell","year":"2019","journal-title":"Am J Prev Med"},{"key":"zoi221218r10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pds.3825","article-title":"Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.","volume":"25","author":"Huerta","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi221218r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States.","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi221218r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002635","article-title":"Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study.","volume":"15","author":"Sidorchuk","year":"2018","journal-title":"PLoS Med"},{"issue":"7","key":"zoi221218r13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.sleep.2009.11.015","article-title":"Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey.","volume":"11","author":"Owens","year":"2010","journal-title":"Sleep Med"},{"issue":"9","key":"zoi221218r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6409a1","article-title":"Controlled substance prescribing patterns\u2014prescription behavior surveillance system, eight states, 2013.","volume":"64","author":"Paulozzi","year":"2015","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"zoi221218r15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013.","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am J Public Health"},{"key":"zoi221218r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.5122","article-title":"Trends in benzodiazepine prescribing for US adolescents and young adults from 2008 to 2019.","author":"Toce","year":"2022","journal-title":"JAMA Pediatr"},{"key":"zoi221218r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2010.11.003","author":"Chhangani","year":"2011","journal-title":"Pediatr Clin North Am"},{"issue":"1-2","key":"zoi221218r18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use.","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi221218r21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0897190013515001","article-title":"Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics.","volume":"27","author":"Jann","year":"2014","journal-title":"J Pharm Pract"},{"key":"zoi221218r22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0022-3956(90)90043-P","article-title":"Benzodiazepines and alcohol.","volume":"24","author":"Linnoila","year":"1990","journal-title":"J Psychiatr Res"},{"key":"zoi221218r23","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"zoi221218r25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.drugalcdep.2017.09.014","article-title":"Characteristics of self-inflicted drug overdose deaths in North Carolina.","volume":"181","author":"Austin","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi221218r26","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-055226","article-title":"Benzodiazepine and stimulant prescriptions before overdose in youth.","volume":"149","author":"Bushnell","year":"2022","journal-title":"Pediatrics"},{"issue":"12","key":"zoi221218r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.28557","article-title":"Association between benzodiazepine use with or without opioid use and all-cause mortality in the United States, 1999-2015.","volume":"3","author":"Xu","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi221218r28","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","article-title":"Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication\u2013Adolescent Supplement (NCS-A).","volume":"49","author":"Merikangas","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"zoi221218r29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaac.2016.01.006","article-title":"Association of lifetime mental disorders and subsequent alcohol and illicit drug use: results from the National Comorbidity Survey\u2013Adolescent Supplement.","volume":"55","author":"Conway","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"zoi221218r30","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1111\/add.2007.102.issue-12","article-title":"Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? results from a national study.","volume":"102","author":"McCabe","year":"2007","journal-title":"Addiction"},{"issue":"7","key":"zoi221218r31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4088\/JCP.v67n0708","article-title":"Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"67","author":"Huang","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"zoi221218r33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5664\/jcsm.26297","article-title":"The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches: a consensus meeting summary.","volume":"1","author":"Owens","year":"2005","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"zoi221218r35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths.","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"zoi221218r37","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/sleep\/30.8.1013","article-title":"Trends in medication prescribing for pediatric sleep difficulties in US outpatient settings.","volume":"30","author":"Stojanovski","year":"2007","journal-title":"Sleep"},{"issue":"4-5","key":"zoi221218r38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/0091217419860716","article-title":"Updates in insomnia diagnosis and treatment.","volume":"54","author":"Bragg","year":"2019","journal-title":"Int J Psychiatry Med"},{"issue":"2","key":"zoi221218r39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5665\/sleep.3410","article-title":"National use of prescription medications for insomnia: NHANES 1999-2010.","volume":"37","author":"Bertisch","year":"2014","journal-title":"Sleep"},{"issue":"5","key":"zoi221218r40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/(ISSN)1099-1557","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi221218r41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamapediatrics.2019.4878","article-title":"Association of opioid prescribing patterns with prescription opioid overdose in adolescents and young adults.","volume":"174","author":"Chua","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"34","key":"zoi221218r42","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.15585\/mmwr.mm7034a2","article-title":"Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019-2020.","volume":"70","author":"Liu","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"zoi221218r43","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1176\/appi.ajp.2020.20071038","article-title":"The risk of overdose with concomitant use of Z-drugs and prescription opioids: a population-based cohort study.","volume":"178","author":"Szmulewicz","year":"2021","journal-title":"Am J Psychiatry"},{"key":"zoi221218r44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, Z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2014a nation-wide register-based open cohort study.","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"zoi221218r45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2016.06.004","article-title":"Insomnia symptoms and suicidality in the National Comorbidity Survey\u2013Adolescent Supplement.","volume":"81","author":"Wong","year":"2016","journal-title":"J Psychiatr Res"},{"issue":"8","key":"zoi221218r46","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s11606-019-05030-6","article-title":"Prescription medications for the treatment of insomnia and risk of suicide attempt: a comparative safety study.","volume":"34","author":"Lavigne","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi221218r48","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.addbeh.2014.01.009","article-title":"Medical and nonmedical use of prescription benzodiazepine anxiolytics among U.S. high school seniors.","volume":"39","author":"McCabe","year":"2014","journal-title":"Addict Behav"},{"key":"zoi221218r19","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","year":"2011","edition":"12th ed"},{"key":"zoi221218r20","unstructured":"US Food & Drug Administration. FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. Accessed October 5, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class"},{"key":"zoi221218r24","unstructured":"National Institute on Drug Abuse. Overdose death rates. Accessed September 10, 2020. https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/overdose-death-rates"},{"key":"zoi221218r32","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). 2020. Accessed September 30, 2021. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt29393\/2019NSDUHFFRPDFWHTML\/2019NSDUHFFR090120.htm"},{"key":"zoi221218r34","unstructured":"Merative. Real-world evidence. Accessed October 19, 2022. https:\/\/www.merative.com\/real-world-evidence?gclid=CjwKCAjwwL6aBhBlEiwADycBIFYejpFrKsCUhbYefIc5J0xs1m7bBcfbYVZjulwt1uuARiM4kQFl5hoCTF8QAvD_BwE&gclsrc=aw.ds"},{"key":"zoi221218r36","unstructured":"Owens? JA. Pharmacotherapy for insomnia in children and adolescents: a rational approach. UpToDate. 2022. Accessed March 4, 2021. https:\/\/www.uptodate.com\/contents\/pharmacotherapy-for-insomnia-in-children-and-adolescents-a-rational-approach\/print"},{"key":"zoi221218r47","unstructured":"U.S. Food and Drug Administration. FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. Accessed March 18, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia"},{"key":"zoi221218r49","unstructured":"Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. Accessed October 20, 2022. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798875\/bushnell_2022_oi_221218_1668448046.67335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T16:00:46Z","timestamp":1669132846000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43215","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}